The Pathologist / Webinars / 2015 / Elucidating Tumor Heterogeneity in Prostate Cancer
ACD Diagnostics Oncology Microbiology and Immunology Histology Genetics and epigenetics Omics

Elucidating Tumor Heterogeneity in Prostate Cancer by Combined IHC & Novel RNA ISH

Assessment of molecular heterogeneity in tumor is a challenging task. For the first time, Palanisamy et al. have demonstrated the existence of a rare subset of prostate cancer with heterogeneous molecular aberrations involving ETS family genes and SPINK1 expression utilizing both standard immunohistochemistry (IHC) and RNA in situ hybridization (Advanced Cell Diagnostics RNAscope® Technology).

01/27/2015

Share

View on demand

TP-webinar_big_2.png

Date: 24 Feb 2015 - 8am Pacific, 11am Eastern US time

Event Overview:

Assessment of molecular heterogeneity in tumor is a challenging task.  For the first time, Palanisamy et al. have demonstrated the existence of a rare subset of prostate cancer with heterogeneous molecular aberrations involving ETS family genes and SPINK1 expression utilizing both standard immunohistochemistry (IHC) and RNA in situ hybridization (Advanced Cell Diagnostics RNAscope® Technology). The presenter will discuss the application of RNA ISH technology to reveal hitherto unidentified molecular subtypes of prostate cancer.

Learning Objectives of Webinar

  1. Strategies for interrogating interpatient and intratumor heterogenity

  2. RNA biomarker analysis of fusion genes, non-coding genes and pseudo genes

  3. Applications of RNAscope ISH along with other methods such as IHC to characterize molecular profiles of tumors

Speaker

Nallasivam Palanisamy, PhD
Associate Scientist

My research interests are on the discovery and characterization of gene fusions in cancer and understanding their role in carcinogenesis from a translational research perspective.

Using genomic technologies such as high-density array comparative genomic hybridization, advanced molecular cytogenetic technologies including FISH, CGH, spectral karyotyping, gene expression microarrays, and next generation sequencing technology, my laboratory investigates the transcriptional and genomic architectures of solid cancer genomes. In-depth analysis of genomic amplifications provided an unprecedented view and identified rare gene fusions formed at the boundaries of amplification and deletions. I also pioneered the application of next generation sequencing technology for the discovery of new recurrent gene fusions in cancer.

0115-801-webinar-sponsor.png

About Us

Advanced Cell Diagnostics is a provider of RNAscope®  Technology, the most sensitive in situ hybridization technology commercially available. Based on ACD’s unique patented probe design strategy which enables simultaneous signal amplification and background noise suppression, RNAscope technology represents one of the most significant advances in ISH technology in over 40 years.  In 2014, applications of this new technology appeared in 83 peer-reviewed publications.

More Webinars

Recommended